Salts, Binary and Ternary Cocrystals of Pyrimethamine: Mechanosynthesis, Solution Crystallization, and Crystallization from the Gas Phase
Source abstract
Abstract
A series of salts and binary and ternary cocrystals of the antimalaria drug pyrimethamine (PYR) are reported. PYR has a donor–acceptor–donor (DAD) and a donor–acceptor (DA) binding site, and cocrystallization experiments were performed with coformers with complementary acceptor-donor-acceptor (ADA) and acceptor-donor (AD) H-bonding functionalities. Three different preparation techniques were compared, namely, solution crystallization, crystallization from the gas phase, and liquid-assisted grinding. In several cases different solid-state forms were obtained depending on the crystallization method. The molecular ionic cocrystals PYRH+BAR–·PYR (BAR = barbituric acid) and (PYRH+SAC–)2·GLU (GLU = glutarimide, SAC = saccharin), the binary cocrystal PYR·GLU, the salt PYRH+NIC– (NIC = nicotinic acid), and two polymorphs of PYRH+SAC– could be crystallized by sublimation. Two other ternary molecular ionic cocrystals, (PYRH+BEN–)·PYR·SUC and (PYRH+SAC–)2·SOR (SUC = succinimide, BEN = benzoic acid, SOR = sorbic acid), were obtained by solution crystallization. Attempts to crystallize ternary cocrystals from solution also yielded a number of new two-component cocrystals including four new solvates of PYRH+SAC–, thus extending the structural landscape of the PYR/SAC system. Liquid-assisted milling was performed as a one-pot reaction and with the stepwise addition of the coformers. The (PYRH+SAC–)2·GLU cocrystal formed when the coformers were milled in one step and when they were added to the mill stepwise. For other systems the outcome of the two-step milling experiment depended on the order in which the coformers were added. The PYR-coformer interactions were analyzed using the PIXEL program.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Crystallography and molecular interactions · Crystallization and Solubility Studies · Phenothiazines and Benzothiazines Synthesis and Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Chemistry, National University of Ireland, Galway H91TK33, Ireland
ITECH Lyon, 87 Chemin des Mouilles, Ecully Cedex 69134, France
Synthesis and Solid State Pharmaceutical Centre, Limerick V94T9PX, Ireland
Funding
Science Foundation Ireland
References (58)
Show source-provided references
1. 10.1016/j.drudis.2008.03.00410.1016/j.drudis.2008.03.004 ↗
2. 10.1002/chem.20190467210.1002/chem.201904672 ↗
3. 10.1039/b811809d10.1039/b811809d ↗
4. 10.1002/1521-3773(20010903)40:17<3240::AID-ANIE3240>3.0.CO;2-X10.1002/1521-3773(20010903)40:17<3240::AID-ANIE3240>3.0.CO;2-X ↗
5. 10.1039/b503718b10.1039/b503718b ↗
6. 10.1039/c3cc43822h10.1039/c3cc43822h ↗
7. 10.1021/jacs.6b0285410.1021/jacs.6b02854 ↗
8. 10.1039/C8CC08135B10.1039/C8CC08135B ↗
9. 10.1039/b707518a10.1039/b707518a ↗
10. 10.1021/acs.cgd.5b0095710.1021/acs.cgd.5b00957 ↗
11. 10.1039/c1cc14567c10.1039/c1cc14567c ↗
12. 10.1002/anie.20140266810.1002/anie.201402668 ↗
13. 10.1039/C5CE01280E10.1039/C5CE01280E ↗
14. 10.1021/cg501115k10.1021/cg501115k ↗
15. Aitipamula S. · CrystEngComm · 2013 · 15 · 587710.1039/c3ce40729b ↗
16. 10.1021/acs.cgd.8b0066210.1021/acs.cgd.8b00662 ↗
17. 10.1021/acs.cgd.7b0173810.1021/acs.cgd.7b01738 ↗
18. 10.1107/S205225251500988410.1107/S2052252515009884 ↗
19. 10.1002/chem.20120357810.1002/chem.201203578 ↗
20. Frisic T. · Angew. Chem., Int. Ed. · 2006 · 45 · 754610.1002/anie.200603235 ↗
21. Bhogola B. R. · Cryst. Growth Des. · 2005 · 5 · 168310.1021/cg058012p ↗
22. 10.1021/ar00172a00510.1021/ar00172a005 ↗
23. 10.1107/S205225251502394510.1107/S2052252515023945 ↗
24. 10.1107/S205225251502395710.1107/S2052252515023957 ↗
25. 10.1021/jacs.7b1250110.1021/jacs.7b12501 ↗
26. 10.1021/cg020027p10.1021/cg020027p ↗
27. 10.1021/cg030015j10.1021/cg030015j ↗
28. Balasubramani K. · Acta Crystallogr. · 2007 · 63 · o4452
29. Balasubramani K. · Anal. Sc. · 2008 · 24 · 251
30. Devi P. · Acta Crystallogr. · 2007 · 63 · o4065
31. 10.1016/j.tet.2005.05.03310.1016/j.tet.2005.05.033 ↗
32. 10.1107/S160053681103257010.1107/S1600536811032570 ↗
33. 10.1107/S205322961801706010.1107/S2053229618017060 ↗
34. 10.1016/j.molstruc.2018.11.08910.1016/j.molstruc.2018.11.089 ↗
35. 10.1107/S160053681401041110.1107/S1600536814010411 ↗
36. 10.1002/chem.20110312910.1002/chem.201103129 ↗
37. Faroque M. U. · Acta Crystallogr. · 2018 · 74 · 100
38. 10.1039/c3ce26765b10.1039/c3ce26765b ↗
39. Nirmalram J. S. · Acta Crystallogr. · 2010 · 66 · o2121
40. 10.1107/S160053680501223710.1107/S1600536805012237 ↗
41. 10.1039/P2984000145910.1039/P29840001459 ↗
42. Giuseppetti G. · Acta Crystallogr. · 1994 · 50 · 1289
43. 10.1002/(SICI)1520-6017(200004)89:4<478::AID-JPS5>3.0.CO;2-510.1002/(SICI)1520-6017(200004)89:4<478::AID-JPS5>3.0.CO;2-5 ↗
44. 10.1107/S010827019601478310.1107/S0108270196014783 ↗
45. 10.1107/S010827019700042510.1107/S0108270197000425 ↗
46. Brittain H. G. · 2009 · 186
47. 10.1021/cg101651p10.1021/cg101651p ↗
48. 10.1021/cg301479c10.1021/cg301479c ↗
49. 10.1021/acs.cgd.8b0108910.1021/acs.cgd.8b01089 ↗
50. 10.1021/acs.cgd.9b0145010.1021/acs.cgd.9b01450 ↗
51. O’Malley C. · ChemComm. · 2020 · 56 · 5657
52. 10.1107/S160057671601844610.1107/S1600576716018446 ↗
53. Sheldrick G. M. · Acta Crystallogr. · 2015 · 71 · 3
54. 10.1107/S205322961402421810.1107/S2053229614024218 ↗
55. 10.1021/acs.cgd.8b0026810.1021/acs.cgd.8b00268 ↗
56. 10.1016/j.molstruc.2020.12818310.1016/j.molstruc.2020.128183 ↗
57. 10.1524/zkri.220.5.499.6506310.1524/zkri.220.5.499.65063 ↗
58. 10.1590/S0101-2061201100020003010.1590/S0101-20612011000200030 ↗